UK markets closed
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • FTSE 250

    23,658.94
    +26.10 (+0.11%)
     
  • AIM

    1,275.74
    +3.60 (+0.28%)
     
  • GBP/EUR

    1.1713
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.3742
    -0.0055 (-0.40%)
     
  • BTC-GBP

    34,360.11
    -513.91 (-1.47%)
     
  • CMC Crypto 200

    1,196.14
    -29.39 (-2.40%)
     
  • S&P 500

    4,435.92
    -37.83 (-0.85%)
     
  • DOW

    34,590.90
    -160.42 (-0.46%)
     
  • CRUDE OIL

    72.07
    -0.54 (-0.74%)
     
  • GOLD FUTURES

    1,753.10
    -3.60 (-0.20%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.91 (+1.03%)
     
  • DAX

    15,490.17
    -161.58 (-1.03%)
     
  • CAC 40

    6,570.19
    -52.40 (-0.79%)
     

Global Companion Diagnostics Market Report 2021: Market to Reach $9.2 Billion by 2027 - U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 14.6% CAGR

·3-min read

Dublin, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Companion Diagnostics Market to Reach $9.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Companion Diagnostics estimated at US$3.4 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at a CAGR of 15.1% over the period 2020-2027.

Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 14.3% CAGR and reach US$6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software & Services segment is readjusted to a revised 16.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 14.6% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • An Introductory Prelude

  • Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development

  • Broader Scope and Applications Rev Up Growth Opportunities

  • Healthy Growth Projected over the Next Few Years

  • Developed Regions: Key Revenue Contributors

  • Market Witnesses Fast Paced Growth in Developing Regions

  • Northbound Trajectory in R&D Spending Creates Conducive Environment

  • Prevailing Economic Scenario Favors Funding Pattern

2. FOCUS ON SELECT PLAYERS (Total 80 Featured)

  • Abbott Molecular

  • Agilent Technologies, Inc.

  • bioMerieux SA

  • Cepheid

  • Danaher Corporation

  • F. Hoffmann-La Roche Ltd.

  • Foundation Medicine Inc.

  • Laboratory Corporation of America Holdings

  • Leica Biosystems Nussloch GmbH

  • Merck & Co. Inc.

  • Myriad Genetics Inc.

  • NeoGenomics Laboratories, Inc.

  • QIAGEN N.V.

  • Quest Diagnostics Inc.

  • Thermo Fischer Scientific Inc.

3. MARKET TRENDS & DRIVERS

  • Growing Significance of Personalized Medicine Remains a Major Market Driver

  • Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum

  • Herceptin Lays the Road for Companion Diagnostics

  • Oncology - Dominant Therapy Area for CDx

  • Rising Incidence of Cancer Propels the Need for CDx Tests

  • Technology Advancements to Widen CDx Use Case

  • PCR: Dominant Technology Type for CDx Testing

  • Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing

  • Significant Role of Biomarkers in Companion Diagnostics

  • Critical Healthcare Needs of Aging Population Underpin CDx Sales

  • Regulatory Scenario Favors CDx Market

  • Resolving Prevailing Challenges: Critical for Future Growth of CDx Market

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 80

For more information about this report visit https://www.researchandmarkets.com/r/yn4tyo

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting